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Abstract: Lacosamide is a newly registered antiepileptic drug with dual mechanisms of action. 
It selectively enhances slow inactivation of voltage-gated sodium channels, resulting in stabi-
lization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing. It 
also binds to a collapsing-response mediator protein-2, CRMP2. Lacosamide has a favorable 
pharmacokinetic profile; is rapidly and completely absorbed, has a relatively long elimination 
half-life of 13 hours which allows twice-daily administration, linear pharmacokinetics, and has 
low potential for drug interactions and renal elimination. Both oral and intravenous formula-
tions of lacosamide are being developed. In placebo-controlled clinical trials, lacosamide was 
effective in seizure reduction as adjunctive therapy in patients with uncontrolled partial-onset 
seizures. Lacosamide was generally well tolerated. The most frequently reported adverse events 
in placebo-controlled trials were dizziness, headache, nausea, and diplopia. Intravenous lacos-
amide has a comparably good safety profile.
Keywords: lacosamide, epilepsy, partial onset seizures
Introduction
Epilepsy is one of the most common neurological disorders, with an annual incidence 
in developed countries of 24–53 cases per 100,000 person-years, and with an age-
adjusted incidence of all unprovoked seizures of 61 per 100,000 person-years.1 The 
age-adjusted prevalence of epilepsy per 1,000 population varies widely; most stud-
ies show a range between 4–8.2 Three percent of the general population have had a 
seizure at some point in their lives. The prevalence of individuals receiving treatment 
for epilepsy is about 1 in 200.3
Epilepsy is characterized by the occurrence of at least two unprovoked episodes of 
periodic disturbance in neurological function, often with altered consciousness, due to 
an abnormal excessive electrical discharge within the brain. In generalized epilepsy 
syndromes, the predominant type of seizures involves early both cerebral hemispheres. 
By contrast, seizures in partial epilepsy syndromes involve a localized portion of one 
hemisphere of the brain at their onset, although they can spread to involve the entire 
brain, a process known as secondary generalization.
Seizures can be classified as being generalized or partial. Generalized seizures 
may be tonic/clonic, isolated tonic or clonic, myoclonic, or absence seizures. Partial 
seizures may be divided into simple partial (motor or sensory) with retained awareness 
or complex partial with impaired awareness. Partial seizures may progress into general-
ized seizures. Partial seizures are the most frequent and most difficult to control.4Neuropsychiatric Disease and Treatment 2010:6 466
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It was also effective against sound-induced seizures in the 
genetically susceptible Frings mouse, against maximal elec-
troshock test (MES)-induced seizures, in the rat hippocampal 
kindling model of partial seizures and in the 6 Hz model of 
psychomotor seizures in mice. Lacosamide failed to show 
efficacy in some other animal models such as picrotoxine, 
bicuculline, and partly in pentylenetetrazol.6
Pharmacokinetics
Lacosamide is absorbed rapidly and completely from the 
gastrointestinal tract after oral administration with negligible 
first-pass effect, and has a high oral bioavailability (approxi-
mately 100%), which is not affected by food.15 Peak plasma 
concentrations are achieved between 0.5 and 4 hours following 
a single dose. Lacosamide has a linear pharmacokinetics; 
plasma concentrations increase proportionally with dose in the 
therapeutic range (50–300 mg intravenous and 100–800 mg 
oral), with low intra- and interpatient variability.14
The elimination half-life of lacosamide is 13 hours and is 
stable in repeated administration. Lacosamide and its metabo-
lites are primarily eliminated renally. The major metabolic 
pathway is demethylation to an O-desmethyl metabolite, 
which has not shown any pharmacological activity. Lacos-
amide has a low pharmacokinetic interaction potential. 
Lacosamide does not inhibit or induce the cytochrome P450 
enzyme family at therapeutic concentrations.14
It has low protein binding (15%).16 Results from clinical 
efficacy and safety trials showed that lacosamide does not affect 
the plasma levels of carbamazepine, valproic acid, lamotrigine, 
levetiracetam, oxcarbazepine, or phenytoin to a relevant extent, 
although the levels of the effective metabolite of oxcarbazepine, 
the monohydroxy-derivative was reduced by 10%–15%.17
Similarly, these drugs do not affect the pharmacokinet-
ics of lacosamide in a clinically relevant manner although 
enzyme-inducing drugs reduced the overall systemic expo-
sure to lacosamide in the phase III study patients. Lacosamide 
does not affect the levels of metformin, digoxin, or oral 
contraceptives.6
Lacosamide solution for infusion (10 mg/mL) is isotonic, 
stable at room temperature, and does not require dilution 
prior to intravenous administration. Intravenous infusion of 
lacosamide at a dose of 200 mg over 30 or 60 minutes has 
shown bioequivalence (maximum plasma concentration, area 
under the curve) to oral lacosamide at the same dose.18
Efficacy
Three multicenter, randomized, double-blind, phase II/III, 
placebo-controlled trials evaluated the efficacy and safety of 
Lacosamide, a new antiepileptic 
drug
introduction
Lacosamide is a new antiepileptic drug recently approved by 
the European Medicines Agency (EMEA) and by the US Food 
and Drug Administration (FDA) in 2008 as adjunctive therapy 
for partial-onset seizures with (EC) or without (EMEA, FDA) 
secondary generalization in patients with epilepsy aged above 
16 years (EC) and 17 years (FDA).5,6 It is available for oral 
and intravenous administration. Traditional antiepileptic drugs 
(AEDs) are effective in suppressing seizure activity; however, 
their utility is limited by significant side effects and by their 
propensity for drug–drug interactions. In the past 15 years, 
multiple second-generation AEDs have been introduced. 
Many of them have better tolerability profiles and a lower drug 
interaction potential. Nevertheless, about a third of patients 
with epilepsy are refractory to available treatments, and a 
significant need for novel drugs remains.7,8
Pharmacodynamics
Lacosamide, (R)-2-acetamido-N-benzyl-3-methoxypropi-
onamide, is a new compound specifically synthesized as an 
anticonvulsive drug candidate.9 In the mid-1980s, it was 
reported that N-acetyl-D,L-alanine benzylamide was effec-
tive in animal models of epilepsy.10 Systematic evaluation 
of more than 100 derivatives of this compound in animal 
models led to the identification of lacosamide.11
Lacosamide seems to have a novel dual mode of action. 
It selectively enhances slow inactivation of voltage-gated 
sodium channels, resulting in stabilization of hyperexcitable 
neuronal membranes and inhibition of repetitive neuronal 
firing without exhibiting effects on physiological neuronal 
excitability (Figure 1).12 Lacosamide also binds to collaps-
ing-response mediator protein-2 (CRMP2), a phosphoprotein 
that is expressed mainly in the nervous system. CRMP-2 is 
involved in neuronal differentiation and network building 
and control of axonal outgrowth and probably also epilep-
togenesis.13 Further research is needed to determine whether 
the interaction between lacosamide and CRMP2 leads to 
symptomatic or disease-modifying effects.14
In preclinical studies, lacosamide was evaluated in the 
antiepileptic drug (AED) development program of the Epi-
lepsy Branch of the National Institutes of Health (NIH) and 
was found to be more potent and effective in several animal 
models compared to other AEDs. Lacosamide inhibited 
N-methyl-D-aspartic acid (NMDA)-induced seizures and 
showed full efficacy in the homocysteine model of epilepsy. Neuropsychiatric Disease and Treatment 2010:6 467
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oral lacosamide when administered concomitantly with up 
to three AEDs in patients with uncontrolled partial-onset 
seizures, with or without secondary generalization. These 
trials were similar in design but different in doses inves-
tigated and ages of the patients enrolled; the doses were 
200 mg, 400 mg, and 600 mg in the SP667 trial, 200 mg 
and 400 mg in the SP755 trial, and 400 mg and 600 mg in 
the SP754 trial.19–21
In all trials, 1,308 patients with a history of an average 
of 23 years of partial-onset seizures were involved. Enrolled 
patients reported an average of at least four partial-onset 
seizures per 28 days, with seizure-free periods no longer than 
21 days, during the eight-week period before enrollment as 
well as during the eight-week baseline period. In these trials, 
patients were randomized to receive adjunctive lacosamide 
or placebo. During the titration period of each trial, the 
lacosamide dose was increased to the randomized dose with 
forced weekly titrations of 100 mg/day (50 mg twice daily). 
This titration period was followed by a 12-week maintenance 
period. Efficacy was evaluated on an intent-to-treat basis with 
analysis of seizure frequency data, comparing maintenance 
data with baseline data.
In the first trial, 418 patients taking one or two con-
comitant AEDs were randomized to placebo or lacosamide 
200 mg, 400 mg, or 600 mg.19 Statistically significant reduc-
tions in seizure frequency per 28 days were observed in the 
400 mg/day (P = 0.002) and 600 mg/day (P = 0.008) lacos-
amide treatment groups, but not in the 200 mg/day group, 
compared with placebo. Statistically significant differences 
in responder rate (number of patients with 50% reduction 
in seizure frequency per 28 days), was significant over pla-
cebo (for which the responder rate was 22%) for lacosamide 
400 mg (41%) (P  =  0.004) and 600 mg/day (38%) (P  =  0.014), 
but was not significant in the 200 mg/day arm.19
In the second trial involving 485 patients taking up to three 
concomitant AEDs and randomized to placebo or lacosamide 
200 mg or 400 mg. Statistically significant reductions in sei-
zure frequency per 28 days were observed in the 200 mg/day 
Figure 1 working modes of voltage-gated sodium channels.   At the resting potential, sodium channels are closed and can be opened by depolarization of the membrane potential 
which allow the flux of sodium ions into the cell.   The channels close within a few milliseconds from inside of the neuron and go into a fast inactivated state from which they 
cannot be reactivated.   when the membrane potential returns to baseline, the sodium channel goes back to its resting state. Under conditions of slight prolonged depolariza-
tion and repetitive neuronal activity, the sodium channel can go into a slow inactivated state by closing the pore from inside. This process happens on a second-to-minute 
time scale. Drugs can either block the open channel (eg, local anesthetics), or enhance fast inactivation (classical anticonvulsants), or enhance slow inactivation (lacosamide). 
Copyright © 2007.  John wiley and Sons. reproduced with permission from Beyreuther B, Freitag J, Heers C, Krebsfänger N, Scharfenecker U, Stöhr T. Lacosamide: a review of 
preclinical properties. CNS Drug Rev. 2007;13:21–42.
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(P = 0.022) and 400 mg/day (P = 0.033) lacosamide treatment 
groups compared with placebo. Statistically significant differ-
ences in responder rate (number of patients with 50% reduction 
in seizure frequency per 28 days) were observed for patients 
treated with lacosamide 400 mg/day (41%) (P = 0.006), 
responder rate was significantly greater for lacosamide 400 mg 
than for placebo (26%).20
In the third trial, 405 patients with partial-onset seizures, 
taking up to three concomitant AEDs were randomized to one 
of three treatment groups: placebo, lacosamide 400 mg/day, 
or lacosamide 600 mg/day. Fifty percent responder rates 
on both dosages tested (400 mg and 600 mg) were sig-
nificantly superior to placebo (38% and 41% versus 18%, 
respectively).21,22
Overall lacosamide showed a clear efficacy measured in 
the proportion of patients with a more than 50% reduction in 
seizure frequency: 40% for lacosamide 400 mg per day, 34% 
for lacosamide 200 mg, and 23% for placebo (Figure 2).23 
A statistically significant reduction in 28-day seizure fre-
quency (baseline to maintenance phase) compared with the 
placebo group was observed with lacosamide 200 mg per day 
in the second trial, 400 mg per day in all three studies, and 
600 mg per day in both studies with this dosage (Figure 3).23 
The efficacy of lacosamide 600 mg per day was similar to that 
of lacosamide 400 mg per day, but patients were less likely 
to tolerate this dose because of central nervous system- and 
gastrointestinal-related adverse effects, therefore the maxi-
mum recommended dose is 400 mg per day.24 In terms of 
seizure freedom, which is most relevant for quality of life, 
results were 2.5%–4.6% of patients randomized to receive 
400 mg per day of lacosamide in different trials rendered 
seizure free. More than 90% of eligible patients who com-
pleted a placebo-controlled trial chose to receive lacosamide 
treatment in an open-label study.
The retention rate was not one of the prespecified outcome 
parameters. However, the retention rate is an important variable 
because it combines aspects of efficacy as well as of tolerabil-
ity. Eighty-six of 97 patients randomized to placebo (89%), 85 
of 107 patients randomized to lacosamide 200 mg/day (79%), 
80 of 108 patients randomized to lacosamide 400 mg/day 
Figure 2 Percentage of patients with at least 50% or 75% reduction in seizure frequency from baseline period to the maintenance period. Pooled efficacy data of SP667, 
SP754, and SP755 trials.
Notes: *P  0.05, **P  0.001 vs placebo. inferential statistics for the 75% responders are not available. Copyright © 2009 expert reviews Ltd. reproduced with permission 
from Beydoun A, D'Souza J, Hebert D, Doty P. Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures. Expert Rev Neurother. 
2009;9(1):33–42.
Abbreviation: LCM, lacosamide.
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(74%), and 61 of 106 patients randomized to lacosamide 
600 mg/day (57%) completed the trial.25
Safety
In the three completed placebo-controlled trials, the most 
frequently reported treatment-emergent adverse events 
were in the nervous and gastrointestinal systems, such as 
dizziness, headache, and nausea.24 Most often these events 
were mild or moderate in intensity. The incidence of diz-
ziness and nausea appeared to be dose-related, increasing 
linearly with increasing doses of lacosamide (Table 1).23 
Discontinuation rates due to adverse events also appeared 
to be related to dose. As a dose of 600 mg/day is not more 
effective and carries the risk of more frequent side effects, 
the highest recommended dose is 400 mg daily. Generally, 
no clinically important changes were observed in body 
weight, laboratory, vital signs or electrocardiography (ECG) 
variables. There was, however, a small dose-related increase 
in PR interval (mean change from baseline at the end of 
maintenance of 4.2 ms to 4.6 ms for the 400 mg/day dose) 
observed on the ECG.19,20
In the open-label extension trials, the types of adverse 
events that emerged with chronic therapy were generally 
similar to those observed in the placebo-controlled trials.24
Serious adverse events occurred in 3%–7% in the 
placebo group, 3%–9% in the lacosamide 200 mg/day group, 
5%–10% in the lacosamide 400 mg/day group, and 3%–10% 
in the lacosamide 600 mg/day group. The serious adverse 
events seen in more than one patient were: worsening of 
seizures, psychotic disorders, dizziness, vomiting, accident, 
and nystagmus.19.20
Intravenous lacosamide
Two intravenous lacosamide trials were carried out. A mul-
ticenter, double-blind, double-dummy, inpatient, random-
ized controlled trial evaluated the safety and tolerability of 
intravenous lacosamide as replacement for oral lacosamide 
for up to two days. Sixty patients from an ongoing open-
label extension trial of oral lacosamide were randomized in 
a 2:1 ratio to either intravenous lacosamide and oral placebo 
or intravenous placebo and oral lacosamide. Half of the 
enrolled patients received 60-minute infusions, and the other 
half received 30-minute infusions. The infusion dosage for 
each patient was (100–300 mg twice daily) was identical 
on a milligram basis to the oral dose of lacosamide that the 
patient had been receiving in the open-label extension trial. 
After completing this trial, patients resumed participation in 
the open-label extension trial with oral lacosamide.26
Figure 3 Median percentage reduction in seizure frequency per 28 days from the baseline period to the maintenance period. Pooled efficacy data of SP667, SP754, and SP755 
trials.
Notes: *P  0.05, **P  0.001 vs placebo. inferential statistics for the 75% responders are not available. Copyright © 2009. reproduced with permission from Beydoun A, D'Souza J, 
Hebert D, Doty P. Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures. Expert Rev Neurother. 2009;9(1):33–42.
Abbreviation: LCM, lacosamide.
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Table 1 incidence of most common treatment emergent adverse effects leading to early discontinuation in the lacosamide 200 mg/day 
and 400 mg/day groups during the treatment period
Kind of side effect Placebo % (n = 364) LCM 200 mg/day % (n = 270) LCM 400 mg/day % (n = 471)
Dizziness 0.3 0.4 4.2
vomiting 0.3 0.4 2.3
Diplopia 0.3 1.5 2.1
Notes: Pooled data of SP667, Sp754, and SP 755 trials. Copyright © 2009. reproduced with permission from Beydoun A, D’Souza J, Hebert D, Doty P. Lacosamide: pharmacology, 
mechanisms of action and pooled efficacy and safety data in partial-onset seizures. Expert Rev Neurother. 2009;9(1):33–42.
Abbreviation: LCM, lacosamide.
A recently completed, multicenter, open-label, inpatient 
trial evaluated the safety and tolerability of intravenous 
lacosamide (100–400 mg twice daily) when administered 
as short-term replacement for oral lacosamide for up to 
five days.27 For the 160 patients enrolled from the ongoing 
open-label extension trials, intravenous lacosamide was 
administered at infusion durations of 30 minutes (n = 40), 
15 minutes (n = 100), or 10 minutes (n = 20). Across all 
infusion durations, most patients received twice-daily doses 
of lacosamide in the 200–400 mg range. Approximately half 
of the patients were exposed to four or five days of treat-
ment with twice-daily infusions of intravenous lacosamide. 
Intravenous lacosamide at doses of 100–400 mg twice daily 
and infusion durations of 60, 30, 15, and 10 minutes dem-
onstrated a comparable safety profile to oral lacosamide. 
Infusion site-related adverse events were infrequent and did 
not result in discontinuation from the trial. A case of a refrac-
tory convulsive status epilepticus successfully controlled with 
lacosamide was reported.28
Bioequivalence between the oral tablet and the oral syrup 
of lacosamide has been established.29
Postmarketing data showed comparable efficacy to 
clinical trials (32% reported a greater than 50% reduction 
in seizure frequency) and more side effects (52%), mostly 
dizziness, fatigue, nausea, gait instability during the titration 
phase and 10% weight loss.30
Conclusion
Lacosamide is a useful antiepileptic drug for difficult-to-
treat partial-onset seizures. Its new mechanism of action 
might indicate a possibility of the drug to be advantageous 
in combination therapy. Its advantages seem to be good 
pharmacokinetics, a low potential for drug–drug interactions 
including oral contraceptives and anticoagulants, which 
make the drug appropriate for broad usage. The favorable 
adverse effect profile lacking sedative effect, the availability 
of an intravenous formulation that may be used for replace-
ment therapy in patients temporarily unable to take oral 
medication, and the antineuralgic effect, useful in patients 
having neuropathy as co-morbidity, are the main features 
of the drug. Disadvantages include the need for slow-dose 
titration and an apparently narrow effective dose range and 
of potential ECG changes suggesting that caution is needed 
before using this drug in patients with pre-existing cardiac 
disease and in those taking class I antiarrhythmics or drugs 
known to cause PR prolongation.19,20
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